Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CTR20262764 GT-818 Advanced cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262764 clinical trial report covering GT-818, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07730021 Carboplatin Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07730021 clinical trial report covering Carboplatin, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07728695 CardiolRx Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07728695 clinical trial report covering CardiolRx, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262747 Quadrivalent inactivated enterovirus vaccine(Beijing Minhai ) Hand, Foot and Mouth Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262747 clinical trial report covering Quadrivalent inactivated enterovirus vaccine(Beijing Minhai ), Phase 1/2, endpoints, sponsor, geography, readout
Latest Hotspot
8 min read
NCT07546929 HP-211 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07546929 clinical trial report covering HP-211, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07730125 CRG-150 PIK3CA mutation/HR-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07730125 clinical trial report covering CRG-150, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07548060 Sacituzumab tirumotecan metastatic non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07548060 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261509 LP-005 Periodontitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20261509 clinical trial report covering LP-005, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07547735 Umbilical cord derived mesenchymal stem cells(Wuhan Union Hospital) Osteoarthritis, Knee Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07547735 clinical trial report covering Umbilical cord derived mesenchymal stem cells(Wuhan Union Hospital), Phase 2, endpoints, sponsor, geography, rea
Latest Hotspot
8 min read
NCT07549061 Vebreltinib Non-Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07549061 clinical trial report covering Vebreltinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07548177 Anlotinib Dihydrochloride Alveolar Soft Part Sarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07548177 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07547813 LAD-328 Hidradenitis Suppurativa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07547813 clinical trial report covering LAD-328, Phase 2, endpoints, sponsor, geography, readout timing and development white space.